The first patient has been enrolled in a phase 2 open-label multicenter study to evaluate intravitreal THR-317, an anti-PIGF antibody, for the treatment of macular telangiectasia type 1, according to a press release from Oxurion.
The study will enroll 10 patients with macular edema caused by macular telangiectasia type 1 (MacTel 1), a rare disease that affects the macula and can lead to vision loss. There is no current effective treatment for MacTel 1.
The study will evaluate the efficacy and safety of the therapy over 2 months via functional and anatomic endpoints.
“The start of this phase 2 study is an important step as we look to expand into additional back of the eye disorders, in line with our mission to enhance vision and fight blindness, alongside our diabetic eye disease pipeline, for which multiple important milestones have been achieved over recent months. Research suggests that PIGF could have an important role to play in MacTel 1, leading us to assess the potential of our anti-PIGF candidate THR-317 in a new eye disease area,” Patrik De Haes, MD, Oxurion CEO, said in the release.